Latest News
Priothera – Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy
Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell trans…
Priothera – Clinical Mocravimod Data in Hematological Malignancies Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Presented at the 2022 European Hematology Association (EHA) Congress
Phase 1b/2a data shows that mocravimod is safe and well tolerated…
Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients
Priothera is working to initiate the MO-TRANS global Phase 2b/3 study in Europe, US and Japan
Priothera Receives FDA clearance of Investigational New Drug (IND)
Global Phase 2b/3 trial (MO-TRANS) assessing the efficacy and safety of mocravimod…
Priothera to present an abstract at the TANDEM Meetings / Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR – April 23-26 2022
The success of allogeneic hematopoietic stem cell transplantation (HSCT)…
Priothera Receives First Regulatory Approvals to Start a Global Pivotal Study with Mocravimod in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Global Phase 2b/3 trial assessing the efficacy and safety of mocravimod…
Priothera Receives R&D Innovation Loan from Bpifrance
€1.5 million loan will further support clinical manufacture of mocravimod…
Priothera presents at EBMT conference March 20-23
Priothera presents at EBMT conference March 20-23
Location, location, location: fighting hematological malignancies by trapping T cells in lymphoid tissue
Priothera’s small molecule mocravimod is transforming the prospects…